Zhan Sutong相关文献与解析，生知库 | 链接生命科学的每一步

A Novel Nomogram for Predicting the Risk of Acute Heart Failure in Intensive Care Unit Patients with COPD

一种用于预测重症监护病房慢性阻塞性肺疾病患者发生急性心力衰竭风险的新型列线图

期刊:Chronic Obstructive Pulmonary Diseases-Journal of the Copd Foundation

影响因子:2

doi:10.15326/jcopdf.2024.0562

Wu, Ziyang; Zhan, Sutong; Wang, Dong; Tang, Chengchun

MDM2 drives resistance to Osimertinib by contextually disrupting FBW7-mediated destruction of MCL-1 protein in EGFR mutant NSCLC

MDM2通过在EGFR突变型非小细胞肺癌中干扰FBW7介导的MCL-1蛋白降解，从而驱动对奥希替尼的耐药性。

期刊:Journal of Experimental & Clinical Cancer Research

影响因子:12.8

doi:10.1186/s13046-024-03220-7

Liu, Jiaxin; Wei, Lingyun; Miao, Qing; Zhan, Sutong; Chen, Peilin; Liu, Wei; Cao, Liang; Wang, Dong; Liu, Hongbing; Yin, Jie; Song, Yong; Ye, Mingxiang; Lv, Tangfeng

LKB1 dictates sensitivity to immunotherapy through Skp2-mediated ubiquitination of PD-L1 protein in non-small cell lung cancer.

LKB1 通过 Skp2 介导的 PD-L1 蛋白泛素化作用，决定非小细胞肺癌对免疫疗法的敏感性

期刊:Journal for ImmunoTherapy of Cancer

影响因子:10.6

doi:10.1136/jitc-2024-009444

Lv Liting, Miao Qing, Zhan Sutong, Chen Peilin, Liu Wei, Lv Jiawen, Yan Wenjie, Wang Dong, Liu Hongbing, Yin Jie, Feng Jian, Song Yong, Ye Mingxiang, Lv Tangfeng

Anlotinib reverses osimertinib resistance by inhibiting epithelial-to-mesenchymal transition and angiogenesis in non-small cell lung cancer.

安罗替尼通过抑制非小细胞肺癌的上皮间质转化和血管生成来逆转奥希替尼耐药性。

期刊:Journal of Biomedical Research

影响因子:2.4

doi:10.7555/JBR.38.20240045

Lyu Liting, Hua Xin, Liu Jiaxin, Zhan Sutong, Zhang Qianqian, Liang Xiao, Feng Jian, Song Yong

[Role of Receptor Tyrosine Kinase AXL in Cancer Targeted Therapy Drug Resistance]

[受体酪氨酸激酶AXL在癌症靶向治疗耐药性中的作用]

A Novel Nomogram for Predicting the Risk of Acute Heart Failure in Intensive Care Unit Patients with COPD

一种用于预测重症监护病房慢性阻塞性肺疾病患者发生急性心力衰竭风险的新型列线图

MDM2 drives resistance to Osimertinib by contextually disrupting FBW7-mediated destruction of MCL-1 protein in EGFR mutant NSCLC

MDM2通过在EGFR突变型非小细胞肺癌中干扰FBW7介导的MCL-1蛋白降解，从而驱动对奥希替尼的耐药性。

LKB1 dictates sensitivity to immunotherapy through Skp2-mediated ubiquitination of PD-L1 protein in non-small cell lung cancer.

LKB1 通过 Skp2 介导的 PD-L1 蛋白泛素化作用，决定非小细胞肺癌对免疫疗法的敏感性

Anlotinib reverses osimertinib resistance by inhibiting epithelial-to-mesenchymal transition and angiogenesis in non-small cell lung cancer.

安罗替尼通过抑制非小细胞肺癌的上皮间质转化和血管生成来逆转奥希替尼耐药性。